Case Study

Overcoming Limitations To Achieve Uniform Dosing

Source: Cambrex

By Tracy Milburn, Director, Analytical Services, Cambrex

iStock-827580992-lab-research-development

Drug companies often consider the value of CDMOs in terms of process development to meet milestones for regulatory filings and scale-up efforts for commercialization. However, specific needs in the clinic can also drive new efforts in method development and drug product formulation. Choosing the right CDMO with the proper experience and facilities can make or break the ability to deliver swift modifications to a formulation.

Formulations of low-dose drugs require a careful balance of several factors to ensure that each dosage has an acceptable blend and content uniformity. Determining the right methods and equipment specifications to pair with the selected material requires expertise across multiple areas of the development process. In this case, an immediate need for lower dose capsules in the clinic posed several challenges in blend formulation with very tight timelines for delivery. With the equipment already optimized to deliver the smallest dose, Cambrex targeted modifications to the formulation to solve the client’s needs. The analytical team worked on multiple fronts while also supporting the manufacturing team, and delivered qualified methods to support release testing of batches of the new formulation.

VIEW THE CASE STUDY!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online